The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q33650768

about

Introduction to Medication Effects on Male Reproduction.High glucose induces the proliferation of prostatic cells via downregulating MRE11.Drugs for benign prostatic hypertrophy

P2860

Q47562497-E1C9223D-7185-42C0-8B39-AD8F00B5D033 Q54095315-45EDA8EF-74EF-43F5-87BA-849FEFB00779 Q58588902-91CED43C-8BE1-45A2-925D-62B7DA80941F

P2860

The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q33650768

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

The impact and management of s ...... benign prostatic hyperplasia.

@ast

The impact and management of s ...... benign prostatic hyperplasia.

@en

type

label

The impact and management of s ...... benign prostatic hyperplasia.

@ast

The impact and management of s ...... benign prostatic hyperplasia.

@en

prefLabel

The impact and management of s ...... benign prostatic hyperplasia.

@ast

The impact and management of s ...... benign prostatic hyperplasia.

@en

P1433

Q33650768-3535D9FB-8B4C-4041-8D5F-C5B5221673BF

P1476

Q33650768-12957D8A-E467-4F34-AF52-93D2B6A2614D

P2093

Q33650768-02522907-2FB7-4DA9-9B94-0A2D7C8C49AD

Q33650768-0EACFBA2-6E28-4875-ADE9-380581B3ABB1

Q33650768-13274DAA-EBE2-4B8F-813F-84910313F82A

Q33650768-35E60B80-8945-468B-8AAF-6DF4AAC9729B

Q33650768-45E570E3-3E99-4481-8AE4-45E1C71A6EB3

Q33650768-59648755-F9AB-4655-A8E1-C32F2E765761

Q33650768-EA41375A-DEF2-4BB4-8A99-0AC581311D34

Q33650768-F710C5D5-E7A5-44D8-8E25-1268B56B7EF7

P2860

Q33650768-06C7EDE1-DBB4-45DF-9C92-2A1AD44D00DD

Q33650768-07E4F917-B2A3-4F7F-8A8A-8D81606A02D3

Q33650768-1037B6A7-18C2-479B-9D9E-B69D65455989

Q33650768-115FCC7C-A6DB-4420-929C-9D49C4667C33

Q33650768-125181A4-2F43-44B0-ACA2-BC2B75A6C638

Q33650768-1A630794-E60B-47A6-9123-6D92EBF0FEA6

Q33650768-1CED377C-938E-48A3-BADD-324376EB7A17

Q33650768-21C3C013-657D-4F30-897F-3A9BCC5F474C

Q33650768-2AC2E115-01BD-4C1C-A673-F53E2EE96DEB

Q33650768-3E157E0B-FD66-4A70-9611-D505117C5284

P304

Q33650768-6E93D369-669D-47B0-87D4-9A09DFFBC118

P31

Q33650768-D939922B-81FB-492D-9639-AD486831D273

P356

Q33650768-A7F4D92C-1FB7-4B4E-BFB7-79520BD66CF3

P433

Q33650768-C8B50EE9-2DFA-436B-B894-64498E000C2B

P478

Q33650768-1AF474B4-0AB4-48C1-B373-25BC67CD432E

P577

Q33650768-211A1888-812F-4D37-941E-C61374E494C9

P698

Q33650768-45479453-00F7-4CAC-99E8-0CD569586E27

P932

Q33650768-41EA322E-25BA-49A4-8959-25A47136B12D

P356

P1433

Translational andrology and urology

P1476

The impact and management of s ...... benign prostatic hyperplasia.

@en

P2093

Anna Zumbo

http://www.w3.org/2001/XMLSchema#string

Gargi Joshi

http://www.w3.org/2001/XMLSchema#string

Gautam Dagur

http://www.w3.org/2001/XMLSchema#string

Jason Gandhi

http://www.w3.org/2001/XMLSchema#string

Noel L Smith

http://www.w3.org/2001/XMLSchema#string

Sardar Ali Khan

http://www.w3.org/2001/XMLSchema#string

Steven A Kaplan

http://www.w3.org/2001/XMLSchema#string

Steven J Weissbart

http://www.w3.org/2001/XMLSchema#string

P2860

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

5alpha-reductase activity in the prostate.

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data.

Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.

Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies.

Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.

Preclinical pharmacology of alpha1-adrenoceptor antagonists.

A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction

Differential expression of two alpha 2-adrenergic receptor subtype mRNAs in human tissues.

P304

295-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TAU.2017.03.57

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28540239

http://www.w3.org/2001/XMLSchema#string

P932

5422692

http://www.w3.org/2001/XMLSchema#string